Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
RESEARCH TOOLSreports
Holding ACRV?
Track your performance easily
ACRV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.19 - $11.90
Previous Close$7.6
Volume232.37K
Average Volume (3M)101.33K
Market Cap
$235.39M
Enterprise Value$59.07M
Total Cash (Recent Filing)$180.54M
Total Debt (Recent Filing)$4.22M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 07, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding30,972,163
10 Day Avg. Volume148,832
30 Day Avg. Volume101,335
Standard Deviation0.27
R-Squared0.01
Alpha0.00815
Financial Highlights & Ratios
Price to Book (P/B)2.18
Price to Sales (P/S)1902.25
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit440.84
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$22.13Price Target Upside192.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Acrivon Therapeutics, Inc. News
PremiumCompany Announcements
Acrivon Therapeutics: Promising Trial Results and FDA Clearance
Bulls Say, Bears Say
Bulls Say
Biomarker EfficacyThe OncoSignature test demonstrated high accuracy in predicting treatment response, achieving statistical significance with a p-value of 0.009.
Clinical Trial ResultsAcrivon's Phase 2 study of ACR-368 in OncoSignature positive endometrial cancer patients showed a remarkable 62.5% overall response rate, significantly outperforming other treatments.
Safety ProfileACR-368 has a favorable safety profile, with low rates of severe side effects and no long-lasting toxicities, making it a safer option compared to other treatments.
Bears Say
Patient ResponseThe BM- patient cohort in both endometrial and ovarian cancers are showing low response rates.
Treatment Adjustment'368 in OncoSig negative patients potentially needs a different combination regimen or an increased dose of gemcitabine to induce deeper responses.
Treatment EffectivenessDepth of response in the ovarian cohort is not robust and the precision medicine ACR-368 is not expected to deepen over time.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $3.19 and its highest was $11.90 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Nov 07, 2024 which is in 49 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Aug 13, 2024. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.603 by $0.083.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -$0.58.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 30,972,162 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.603. Following the earnings report the stock price went down -4.48%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Among the largest hedge funds holding Acrivon Therapeutics, Inc.’s share is RA Capital Management. It holds Acrivon Therapeutics, Inc.’s shares valued at 48M.
---
Acrivon Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.13 (192.72% Upside)
$22.13 (192.72% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 5.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 16.2%
Last 30 Days ▲ 21.7%
Last 30 Days ▲ 21.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.96%
12-Months-Change
Fundamentals
Return on Equity
-37.78%
Trailing 12-Months
Asset Growth
44.07%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
---
ACRV Stock 12 Month Forecast
Average Price Target
$22.13
▲(192.72% Upside)
Technical Analysis
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+2.63%
reiterated a buy rating 5 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +2.63% per trade.
---